Clinical-stage biotechnology company Biophytis SA (Euronext Growth Paris:ALBPS) (OTC:BPTSY) announced on Thursday that it has received Investigational New Drug (IND) approval from the US Food and Drug Administration (FDA) to begin a Phase 2 clinical study of BIO101 (20-hydroxyecdysone) in obesity.
The study will measure muscle strength, mobility and body composition. It is due to start mid-2024 in the United States and could be extended to Europe.
Biophytis expects preliminary results in 2025 and is seeking funding and partnerships to complete the study.
AstraZeneca invests USD2bn in Summit Therapeutics to advance ADC and cancer-drug combinations
BRC Therapeutics participates in regulators' workshop advancing botanical drug development
Lupin announces receipt of US FDA tentative approval for Apixaban Oral Suspension
QIAGEN completes US QIAstat-Dx bloodstream infection portfolio with FDA clearance
Innovent expands global Phase 3 study of IBI363/TAK-928 to include non-squamous NSCLC
FDA approves WELIREG and LENVIMA combination for previously treated advanced renal cell carcinoma
AstraZeneca's IMFINZI combination receives US Priority Review for muscle-invasive bladder cancer
XtalPi submits US FDA IND application for KQTD-126 in chronic intestinal pain
Revvity launches IVDR-certified solution for early detection of type 1 diabetes
FDA Advisory Committee votes in favour of GRAIL's Galleri multi-cancer early detection test